Can Thymidine Phosphorylase Be a Predictive Marker for Gemcitabine and Doxifluridine Combination Chemotherapy in Cholangiocarcinoma?

@inproceedings{Kang2014CanTP,
  title={Can Thymidine Phosphorylase Be a Predictive Marker for Gemcitabine and Doxifluridine Combination Chemotherapy in Cholangiocarcinoma?},
  author={Myoung Hee Kang and Won Sup Lee and Se-il Go and Moon Jin Kim and Un Seok Lee and Hye Jung Choi and Dong Chul Kim and Jeong-hee Lee and Hoon-Gu Kim and Kyung Soo Bae and Jae Min Cho and Ming-hui Wu.},
  booktitle={Medicine},
  year={2014}
}
Unresectable cholangiocarcinoma is poorly responded to chemotherapy, especially for the case refractory to gemcitabine and cisplatin. Here, we tested whether high expression of thymidine phosphorylase (TP) can be a predictive biomarker for the indicator for gemcitabine and doxifluridine combination chemotherapy in the cholangiocarcinoma refractory to… CONTINUE READING